Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.

Investigational new drugs - 1 Apr 2021

Fukudo Masahide, Tamaki Gaku, Azumi Makoto, Kakizaki Hidehiro, Matsumoto Seiji, Tasaki Yoshikazu

Abstract excerpt

Purpose Axitinib is an orally active multikinase inhibitor currently used to treat patients with metastatic renal cell carcinoma (RCC). This study examined the pharmacokinetics of axitinib and the relationship between peak drug concentration (Cmax) and clinical outcomes in real-world practice. Methods Twenty patients with metastatic RCC treated with axitinib monotherapy were enrolled. Post-dose (1-4 h) blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Drug Monitoring

Share to Intestinal Absorption

Share to Kidney Neoplasms

Share to Neoplasm Proteins

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 33098047
DOI: 10.1007/s10637-020-01023-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.PMID 33098047Read ↗

Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.Semantic proximity Read ↗

Population pharmacokinetic analysis of axitinib in healthy volunteers.Semantic proximity Read ↗

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.Semantic proximity Read ↗

In Vitro Kinetic Characterization of Axitinib Metabolism.Semantic proximity Read ↗

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.Semantic proximity Read ↗

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.Semantic proximity Read ↗

Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumorsSemantic proximity Read ↗

Tumor growth inhibition modeling to support the starting dose for dacomitinib.Semantic proximity Read ↗

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.Semantic proximity Read ↗

Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.Semantic proximity Read ↗

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.Semantic proximity Read ↗

Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.